CENTOGENElogo.jpg
CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development
July 27, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting
June 25, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years
June 22, 2021 06:30 ET | CENTOGENE GmbH
Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeuticsFocuses on leveraging its unique rare...
CENTOGENElogo.jpg
CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia
June 02, 2021 06:31 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 02, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution
June 01, 2021 06:30 ET | CENTOGENE GmbH
World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient casesNEW CentoXome® provides...
CENTOGENElogo.jpg
CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals
May 18, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENElogo.jpg
CENTOGENE Extends Global Parkinson’s Disease Study
May 10, 2021 06:30 ET | CENTOGENE GmbH
Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to...
CENTOGENElogo.jpg
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
May 06, 2021 06:30 ET | CENTOGENE GmbH
Database has grown to more than 465,000 analyzed patients, with more than 225,000 being linked to HPO termsRelease includes increase of almost 19 million to over 31 million unique variants New...
CENTOGENElogo.jpg
CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank
May 05, 2021 06:30 ET | CENTOGENE GmbH
More than half of patients with genetic diseases remain undiagnosed, even after performing Exome and Genome SequencingBy performing deep genetic analyses and Bio/Databank mining, CENTOGENE discovers...
CENTOGENElogo.jpg
CENTOGENE Announces Nomination of Jonathan Sheldon to Supervisory Board
November 13, 2020 11:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2020 (GLOBE NEWSWIRE) -- CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical...